Eleni Tholouli

Oxford Road
Manchester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 79 publications

Erratum to: "Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/ refractory B-cell acute lymphoblastic leukemia".

Erratum to: "Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/ refractory B-cell acute lymphoblastic leukemia".

Journal: Haematologica

Published: August 01, 2026

Donor HLA-E*01:06 Confers Protection from Relapse and Improved Survival after T cell depleted Matched Unrelated Donor Haematopoietic Cell Transplantation.

Donor HLA-E*01:06 Confers Protection from Relapse and Improved Survival after T cell depleted Matched Unrelated Donor Haematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: June 16, 2026

Timing is everything: outcomes of allogeneic HSCT in adults with inborn errors of immunity.

Timing is everything: outcomes of allogeneic HSCT in adults with inborn errors of immunity.

Journal: Bone marrow transplantation

Published: April 26, 2026

Improved progression free survival after axicabtagene ciloleucel compared to tisagenlecleucel, in patients aged >70 years with large B-cell lymphoma.

Improved progression free survival after axicabtagene ciloleucel compared to tisagenlecleucel, in patients aged >70 years with large B-cell lymphoma.

Journal: Haematologica

Published: January 15, 2026

CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study.

CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study.

Journal: Cancer research communications

Published: December 17, 2025

Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT.

Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT.

Journal: Bone marrow transplantation

Published: November 19, 2025

Results from the prospective phase 2 multicentre UK PBSC haplo trial using PTCy pre- or post-stem cells.

Results from the prospective phase 2 multicentre UK PBSC haplo trial using PTCy pre- or post-stem cells.

Journal: British journal of haematology

Published: October 17, 2025

Landscapes of HLA Mismatching in Contemporary Unrelated Haematopoietic Cell Transplantation.

Landscapes of HLA Mismatching in Contemporary Unrelated Haematopoietic Cell Transplantation.

Journal: HLA

Published: July 09, 2025

Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Journal: Haematologica

Published: July 02, 2025

An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant.

An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: June 25, 2025

Workforce consensus recommendations for paediatric haematopoietic stem cell transplant centres on behalf of the Paediatric Sub-Committee of the British Society of Blood and Marrow Transplantation and Cellular Therapy.

Workforce consensus recommendations for paediatric haematopoietic stem cell transplant centres on behalf of the Paediatric Sub-Committee of the British Society of Blood and Marrow Transplantation and Cellular Therapy.

Journal: British journal of haematology

Published: April 04, 2025

Results From a UK Consensus via Delphi on Practical Considerations Surrounding Risk Assessment and Patient Monitoring for a Prompt Diagnosis of Severe Veno-Occlusive Disease (VOD) in Adults Post-HSCT.

Results From a UK Consensus via Delphi on Practical Considerations Surrounding Risk Assessment and Patient Monitoring for a Prompt Diagnosis of Severe Veno-Occlusive Disease (VOD) in Adults Post-HSCT.

Journal: EJHaem

Published: March 19, 2025

Showing 1-12 of 79

Last Updated: 09/26/2026